Head to Head Analysis: Qiagen (QGEN) and PRA Health Sciences (PRAH)

Qiagen (NASDAQ: QGEN) and PRA Health Sciences (NASDAQ:PRAH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Valuation and Earnings

This table compares Qiagen and PRA Health Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $1.34 billion 5.39 $80.40 million $0.39 81.21
PRA Health Sciences $1.81 billion 2.86 $68.17 million $1.78 45.98

Qiagen has higher earnings, but lower revenue than PRA Health Sciences. PRA Health Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

62.4% of Qiagen shares are held by institutional investors. Comparatively, 98.5% of PRA Health Sciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 2.1% of PRA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Qiagen and PRA Health Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 6.40% 11.36% 6.37%
PRA Health Sciences 5.64% 21.66% 7.02%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Qiagen and PRA Health Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 7 5 0 2.42
PRA Health Sciences 0 1 9 0 2.90

Qiagen presently has a consensus price target of $33.36, suggesting a potential upside of 5.33%. PRA Health Sciences has a consensus price target of $89.70, suggesting a potential upside of 9.59%. Given PRA Health Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe PRA Health Sciences is more favorable than Qiagen.

Risk and Volatility

Qiagen has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, PRA Health Sciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Summary

PRA Health Sciences beats Qiagen on 9 of the 14 factors compared between the two stocks.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

About PRA Health Sciences

PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company’s service offerings include product registration, strategic solutions and early development services.

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply